Relationship between retinal volume changes and the prognosis of BRVO-ME treated with ranibizumab.

ABSTRACT:

Background

This study aimed to evaluate the efficacy of ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO-ME), changes in retinal volume and central retinal thickness (CRT) before and after therapy, and the connection between visual prognosis and changes in retinal volume.

Methods

The 120 patients(121 eyes) of BRVO-ME were recruited from July 2020 to October 2022 at the Affiliated Hospital of Weifang Medical University. The clinical data of patients were retrospectively examined for changes in best-corrected visual acuity (BCVA), retinal volume, and CRT at 1 day, 1 week, 1 month, 3 months, 6 months and 1year after treatment.

Findings

Visual acuity improved gradually and became steady approximately 1 months after treatment,

SUBMITTER: Xing Z 

PROVIDER: S-EPMC11336588 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature